Related Experiment Video

Updated: Jan 31, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Bifunctional Fusion Proteins Derived from Tumstatin and 4-1BBL for Targeted Cancer Therapy

Chao Sun1, Dongyang He1, Chao Ma1

  • 1State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology , China Pharmaceutical University , Nanjing 210009 , China.

Molecular Pharmaceutics
|December 20, 2018
PubMed

Insights

A novel bifunctional fusion protein, rh4TFP-2, combines antiangiogenesis and immunotherapy to target cancer. This approach effectively inhibits tumor growth and enhances T lymphocyte activation, offering a promising new cancer therapy.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Antiangiogenesis and immunotherapy are established cancer treatments.
  • Combining these strategies may enhance therapeutic effectiveness.
  • Tumstatin inhibits angiogenesis, while 4-1BBL costimulates T lymphocytes.

Purpose of the Study:

  • To construct and evaluate a recombinant human 4-1BBL/tumstatin fusion protein (rh4TFP) library.
  • To assess the antiangiogenic and immunotherapeutic potential of rh4TFP variants.
  • To identify an optimal fusion protein for combined cancer therapy.

Main Methods:

  • Construction of a recombinant human 4-1BBL/tumstatin fusion protein (rh4TFP) library with varying linkers.
  • In vitro assessment of rh4TFP-2's effects on endothelial cell proliferation and migration.
  • In vitro analysis of T lymphocyte activation markers (IL-2, IFN-γ) upon rh4TFP-2 exposure.
  • In vivo evaluation of rh4TFP-2 efficacy in a B16F10 melanoma mouse model.

Main Results:

  • rh4TFP-2 demonstrated significant antiangiogenic activity by inhibiting endothelial cell proliferation and migration.
  • rh4TFP-2 effectively promoted T lymphocyte activation, evidenced by increased IL-2 and IFN-γ release.
  • Administration of rh4TFP-2 suppressed tumor growth and improved survival rates in a preclinical mouse model.

Conclusions:

  • rh4TFP-2 exhibits potent antiangiogenic and immunotherapeutic properties.
  • Bifunctional fusion proteins targeting both angiogenesis and T lymphocyte activation represent a novel strategy for cancer treatment.
  • rh4TFP-2 shows promise for clinical development in cancer therapy.
Keywords:
4-1BBLantiangiogenesisbifunctional fusion proteinscancer immunotherapytumstatin

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.5K
Nuclear Fusion02:45

Nuclear Fusion

The process of converting very light nuclei into heavier nuclei is also accompanied by the conversion of mass into large amounts of energy, a process called fusion. The principal source of energy in the sun is a net fusion reaction in which four hydrogen nuclei fuse and ultimately produce one helium nucleus and two positrons.
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
33.9K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
SNAREs and Membrane Fusion01:43

SNAREs and Membrane Fusion

Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
12.7K